Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NeoplasmsThis trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
0 and up
Critères de participation
Inclusion Criteria:
* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.
Exclusion Criteria:
- None
Lieu de l'étude
Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-RosemontMontreal, Quebec
Canada
Contactez l'équipe d'étude
Princess Margaret Cancer Centre
Princess Margaret Cancer CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Adaptimmune
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT03391778